Multicenter phase II trial of nab-paclitaxel and cisplatin (AP) followed by chemoradiation therapy (CRT) for locally advanced head and neck squamous cell carcinoma (HNSCC)
Douglas R. Adkins(Washington University in St. Louis), Peter Oppelt(Washington University in St. Louis), Jason T. Rich(Washington University in St. Louis), P. Neupane(University Medical Center), Patrik Pipkorn(Washington University in St. Louis), José P. Zevallos(University of Pittsburgh Medical Center), Jessica Ley(Washington University in St. Louis), Randal C. Paniello(Washington University in St. Louis), Mackenzie Daly(University of Colorado Colorado Springs), Wade L. Thorstad(Washington University in St. Louis), Hiram A. Gay(Washington University in St. Louis), Kathryn Trinkaus(Washington University in St. Louis), Ryan S. Jackson(Washington University in St. Louis)
Cited by 1
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial
|The Lancet Oncology|2013|748
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018
|Journal of the National Comprehensive Cancer Network|2018|632
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022
|Journal of the National Comprehensive Cancer Network|2022|532